Drug utilization review of cholinesterase inhibitors in Quebec

Canadian Journal of Neurological Sciences

Volumn 35, Issue 4, 2008, Pages 508-509

  Massoud, Fadi ^a   Dorais, Marc ^a   Charbonneau, Claudie ^b   Lescrauwaet, Bénédicte ^b   Boucher, Jean Marc ^a   LeLorier, Jacques ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; RIVASTIGMINE;

ADULT; AGED; CANADA; CONTROLLED STUDY; DEMENTIA; DEMOGRAPHY; DRUG UTILIZATION; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SERVICE; MEDICAL SPECIALIST; PRESCRIPTION; PRIORITY JOURNAL; REIMBURSEMENT; REVIEW; SEX DIFFERENCE;

EID: 55049120280     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100009215     Document Type: Review

References (5)

1. Canadian study of health and aging. Study methods and prevalence of dementia. Can Med Assoc J. 1994;150:899-13.
2. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol. 1992;45: 197-203.
3. Herrmann N, Gill SS, Bell CM, Anderson GM, Bronskill SE, Shulman KE, et al. A population-based study of cholinesterase inhibitor use for dementia. J Am Geriatr Soci. 2007;55:1517-23.
4. Suh DC, Thomas SK, Valiyeva E, Arcona S, Vo L. Drug persistency of two cholinesterase inhibitors: rivastigmine versus donepezil in elderly patients with Alzheimer's disease. Drugs Aging. 2005; 22:695-07.
5. Singh G, Thomas SK, Arcona S, Lingala V, Mithal A. Treatment persistency with rivastigmine and donepezil in a large state medicaid program. J Am Ger Soc. 2005;53:1269-70.